Proteomic profiles associated with postsurgical progression in non-functioning pituitary adenomas.

Hallén T, Johannsson G, Thorsell A, Olsson DS, Örndal C, Engvall A, Jacobson F, Widgren A, Bergquist J, Skoglund T

J. Clin. Endocrinol. Metab. - (-) - [2023-12-29; online 2023-12-29]

There is a lack of reliable biomarkers capable of predicting postoperative tumor progression of non-functioning pituitary adenomas (NFPAs). To discover proteomic profiles associated with postoperative tumor progression in patients with NFPA. Case-controlled exploratory study. Tertiary university hospital. Tissue samples were obtained from 46 patients with residual tumor following surgery for NFPA of gonadotroph lineage. Two patient groups were compared: patients requiring reintervention due to residual tumor progression (cases; reintervention group, n=29) and patients with a residual tumor showing no progression for a minimum of 5 years (controls; radiologically stable group, n=17). None. Differentially expressed proteins (DEPs) between patient groups. Global quantitative proteomic analysis identified 4074 proteins, of which 550 were differentially expressed between the two groups (fold change>80%, false discovery rate-adjusted P≤0.05). PCA showed good separation between the two groups. Functional enrichment analysis of the DEPs indicated processes involving Translation, ROBO-receptor signaling, Energy metabolism, mRNA metabolism, and RNA splicing. Several upregulated proteins in the reintervention group, including SNRPD1, SRSF10, SWAP-70, and PSMB1, are associated with tumor progression in other cancer types. This is the first exploratory study analyzing proteomic profiles as markers of postoperative tumor progression in NFPA. The findings clearly showed different profiles between tumors with indolent postoperative behavior and those with postoperative tumor progression. Both enriched pathways involving DEPs and specific upregulated proteins have previously been associated with tumor aggressiveness. These results suggest the value of proteomic profiling for predicting tumor progression in patients with NFPA.

Glycoproteomics and MS Proteomics [Collaborative]

PubMed 38157275

DOI 10.1210/clinem/dgad767

Crossref 10.1210/clinem/dgad767

pii: 7503831